Investigation of the pathogenesis and establishing the pharmacotherapy for the early repolarization syndrome and refractory epilepsy caused by KCND3 variants using iPSC models.

• Project/Area Number: 24K19074
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53020:Cardiology-related
• Research Institution: National Cardiovascular Center Research Institute
• Principal Investigator: ビャムバジャブ ツェレンハム 国立研究開発法人国立循環器病研究センター, オープンイノベーションセンター, リサーチフェロー (60963527)
• Project Period (FY): 2024-04-01 – 2027-03-31
• Project Status: Granted (Fiscal Year 2024)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2026: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2025: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2024: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: KCND3 / ERS / Refractory Epilepsy / iPSC-cardiomyocytes / SSRIs

Outline of Research at the Start

I. Elucidate the pathogenesis of Early Repolarization Syndrome (ERS) and refractory epilepsy (RE): Generation of iPSC-derived cardiomyocytes and neurons with KCND3 and evaluate functional characteristics.

II. Pharmacological evaluation on mutant Ito channel: Effect of quinidine, fluoxetine, and other Selective Serotonin Reuptake Inhibitors (SSRIs) in iPSC-cardiomyocytes and neurons.